Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J D Davis

Showing results (121-130 of 124) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 124 results.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 7, 2020
A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacyA S Paller, E C Siegfried, E L Simpson, et al.
Cancer Research|July 14, 1998
Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculatureA K Sills, J I Williams, B M Tyler, et al.
The British Journal of Dermatology|October 10, 2019
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extensionM J Cork, D Thaçi, L F Eichenfield, et al.
The British Journal of Dermatology|March 10, 2019
Conjunctivitis in dupilumab clinical trialsB Akinlade, E Guttman-Yassky, M de Bruin-Weller, et al.
Pageof 13

Showing results (121-130 of 124) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 124 results.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 7, 2020
A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacyA S Paller, E C Siegfried, E L Simpson, et al.
Cancer Research|July 14, 1998
Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculatureA K Sills, J I Williams, B M Tyler, et al.
The British Journal of Dermatology|October 10, 2019
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extensionM J Cork, D Thaçi, L F Eichenfield, et al.
The British Journal of Dermatology|March 10, 2019
Conjunctivitis in dupilumab clinical trialsB Akinlade, E Guttman-Yassky, M de Bruin-Weller, et al.
Pageof 13